The US Food and Drug Administration (FDA) has approved Emergent BioSolutions’ supplemental Biologics License Application (sBLA) for the manufacture of ACAM2000, the only FDA-licensed smallpox vaccine, as the company looks to expand its CMO services.
The completion of trial batches of Siga Technologies’ smallpox treatment ST-246 could not have been better timed following as it does the recomendation that the Obama government raise the threat of bio-terror up its list of concerns.
A multi-million dollar US manufacturing contract for Acambis hinges
on whether or not the firm can satisfy the Food and Drug
Administration (FDA) that its investigational smallpox vaccine
should be approved.
Danish biopharmaceutical firm Bavarian Nordic has received approval
from Denmark's government to begin large-scale commercial
production of smallpox vaccine based on its Modified Vaccinia
Ankara (MVA) virus strain which demonstrates...
In today's increasingly tense socio-political climate, with the
threat of bioterrorism looming ever larger, the race to find an
effective drug therapy for one of the world's most feared diseases
- smallpox - is hotting...
Scientists studying vaccinia virus, a close relative of smallpox,
have discovered that a gene necessary for virus replication also
plays a key role in turning off inflammation, a crucial antiviral
immune response of host cells.
Denmark-based vaccines company Bavarian Nordic is investing DK 250
million (€33.6m) in a production facility that will be the largest
of its kind in Europe, producing up to 120 million vaccine doses a